secwatch.observer — SEC 8-K summary
======================================

Issuer:     SERA PROGNOSTICS, INC. (SERA)
CIK:        0001534969
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001534969-23-000121
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sera Prognostics PRIME study meets efficacy endpoint at interim; enrollment stopped
--------------------------------------------------------------------------------

- DSMB recommended stopping PRIME study enrollment after one co-primary endpoint met efficacy stopping criteria at interim.
- Company adopted DSMB recommendation; will stop enrollment to focus on analyzing and reporting available data.
- CEO Zhenya Lindgardt described early stop as 'unexpected' and 'encouraging,' citing consistency with prior PREVENT and AVERT studies.
- The PRIME trial is pivotal for the PreTRM® test, which aims to predict preterm birth risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534969/000153496923000121/0001534969-23-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534969/000153496923000121/sera-20231206.htm
  HTML page:      https://secwatch.observer/filing/0001534969-23-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer